Volume : 11, Issue : 03, March – 2024
Title:
A REVIEW ON ALCOHOLIC LIVER DISEASE
Authors :
Ms. Reeba Roy, Mrs. Soumya R V, Dr. Prasobh G R, Ms. Hashima Asim Khan, Ms. Shanuja D
Abstract :
Alcoholic liver disease is damage to the liver. The risk of developing the disease is related to the quantity and duration of alcohol consumption. The prevalence is highest in European countries. The most complications occur are Jaundice, Hepatic encephalopathy, Cirrhosis, Steatosis etc. This can be treated by liver biopsy, endoscopy. Alcohol intake increases NADHNAD+ in hepatocytes. The alcohol metabolism increases the production of NADH by reducing NAD in the body. Ongoing liver injury leads to irreversible liver damage.
Key words: Alcoholic steatosis or Alcoholic fatty liver, Alcoholic hepatitis, Alcoholic cirrhosis
Cite This Article:
Please cite this article in press Reeba Roy et al., A Review On Alcoholic Liver Disease ,, Indo Am. J. P. Sci, 2024; 11 (03).
Number of Downloads : 10
References:
1. Sepanlou S G, Safiri S, Bisignano C, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systemic analysis for the Global Burden of Disease Study 2017-2020;5:245-266.
2. Ashwani SKMD, Bataller MSFACGI, Ramon MD, Joseph AMD, Kamath Patrick S MD4, Shah Vijay H MD, FACG4 ACG Clinical Guideline: Alcoholic Liver Disease, American Journal of Gastroenterology. 2018, 113(2): 175-194.
3. Ferenczi P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, et al. Randomised controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol, 1989; 9: 105-113.
4. Parthasarathi G, Nyfort-Hansen K, Nahata MC, The textbook of Clinical Pharmacy Practice, Second edition. 2012; 447-464.
5. Savolainen VT et al. Alcohol consumption and Alcoholic liver disease: Evidence of threshold level of effects of ethanol. Alcoholism: Clinical and Experimental Research. 1993; 17(5): 1112-1117.
6. Stickel F, Datz C, Hampe J, et al. pathophysiology of alcoholic liver disease: 2017; 11(2): 173-188.
7. Zeebaish S, et al. A prospective observational study on prescribing patterns of drugs used in alcoholic liver disease patients at a tertiary care teaching hospital. International Journal of Basic and Clinical Pharmacology. 2017; 6(6): 1386-1392.
8. Patil AM, Arifulla M, Yendigeri SM, Sajanar BB. Study of Alcoholic Liver Cirrhosis in Hospital-Based Patients, Bijapur, Northern Karnataka, India. International Journal of Current Medical and Applied Sciences. 2015; 7(1): 16-20.
9. Biradar SM, Gelada D, Mounika MV, Meghana P, Bharathi M, Ambali AP, et al. Assessment of clinical profile and treatment chart review for alcoholic liver disease patients: a prospective and observational study. Journal of Drug Delivery and Therapeutics. 2018; 8(5): 437-441.
10. Strieter RM, Remick DG, Ward PA, et al. Cellular and Molecular regulation of tumour necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6.
11. Kershenobich D, Vargas F, Garcia-Tsao G, Perez Tamayo R, Gent M, Rojkind M. Colchicine in the treatment of liver cirrhosis. N Engl J Med. 1988;318: 1709-13.
12. Stickel F, Datz C, Hampe J, et al. management of alcoholic liver disease: 2017; 11(2): 173-188.
13. Sachdeva A, Choudhary M, Chandra M. Patient counselling of alcoholic liver disease; J Clin Diagn Res. 2015; 9(9): VE01-VE07.
14. Rodriguez-Moran M, Guerrero-Romero F, Efficacy of pentoxifylline in the management of microalbuminuria in patients with Diabetes. 4(1): 55-62.